Livingston, N.J.-based Reprogenetics offers pre-implantation genetic screening and diagnosis for in vitro fertilization, Cooper said. The $46.5 million deal isn’t expected to affect earnings per share this year or in 2016, but should be accretive thereafter, the company said.
Reprogenetics put up sales of roughly $20 million during the 12 months ended July 31, Cooper said. Low-double-digit growth is forecast for the coming years, according to a press release.
“The acquisition of Reprogenetics strengthens our industry-leading IVF business by positioning us at the forefront of the emerging field of genetic testing targeted to improving IVF pregnancy rates while helping to eliminate severe genetic disorders,” president & CEO Robert Weiss said in prepared remarks.
Cooper is based in Pleasanton, Calif.